Accriva Diagnostics directCHECK ACT-LR quality control recalled for incorrect labeling
Accriva Diagnostics' directCHECK ACT-LR whole blood quality control product (level 2, lot A6DLA001) has incorrect performance range information on its label. This labeling error could lead to misinterpretation of test results if the correct reference range is not known.
From the FDA notice · Read the official notice ↗ · All Accriva Diagnostics recalls
What to do
- Check if your laboratory uses directCHECK ACT-LR level 2 from lot A6DLA001
- Contact Accriva Diagnostics or your supplier for corrected labeling or instructions
- Do not use the product until you have confirmed the correct performance range with the manufacturer
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
Details
- Units affected
- 6060
- Illnesses reported
- None reported
- Manufactured in
- 6260 Sequence Dr, San Diego, CA, United States
- Classification
- Class II
- Recall number
- Z-2460-2026
In the FDA's words
- Description
- directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2 Assayed Whole blood control contains labeling with incorrect performance range. Lot #: A6DLA001 Unique Device Identifier: 10711234170373 Distribution: Worldwide - US Nationwide distribution including in the states of AL, AR, AZ, CA, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, MT, NC, NJ, NM, NY, OH, OK, PA, SC, TN, TX, VA, VT, WA, WI, WV and the countries of Canada, Hong Kong, Spain. Affected quantity: 6060
- Hazard
- Assayed Whole blood control contains labeling with incorrect performance range.
More from Accriva Diagnostics
See all- Accriva Hemochron Jr. APTT cuvettes recalled for inaccurate results
ModerateFDAOct 30, 2026